Hongbo Lu
Hongbo Lu

Prior to joining LAV, Dr. Lu served as a Managing Director at OrbiMed Advisors between 2011 – 2016 when she spearheaded the efforts in building a billion-dollar emerging market hedge fund portfolio for the firm. Previously, she was a Principal and a Senior Research Analyst at Piper Jaffray & Co between 2006 – 2011. Dr. Lu has close to 20 years of investment and operational experience in the healthcare industry. She served or is serving on multiple company boards including CrownBio, Echosens, TP Therapeutics, Avedro, Centrexion, and PINS, among others. Dr. Lu received a Ph.D. in BioEngineering from the University of Washington, an M.B.A. from the Haas School of Business at the University of California, Berkeley, and graduated with honors from Tsinghua University in China.